

Clinical Study Protocol Version (a) H0P-MC-NP01

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain.

NCT04476108

Approval Date: 27-Mar-2020

## Title Page

### Intervention-Specific Appendix (ISA) for LY3016859: H0P-MC-NP01(a)

#### Confidential Information

The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of LY3016859, unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries.

**Note to Regulatory Authorities:** This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.

**Master Protocol Title:** A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain

**Master Protocol Number:** H0P-MC-CPMP

**ISA Title:** Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain.

**ISA Number:** H0P-MC-NP01

**Amendment Number:** (a)

**Compound:** LY3016859

**Study Phase:** 2

**Acronym:** NP01

**Sponsor Name:** Eli Lilly and Company

**Legal Registered Address:** Indianapolis, Indiana USA 46285

**Regulatory Agency Identifier Number(s)**

Master Protocol IND: 144915

**Approval Date:** Protocol Electronically Signed and Approved by Lilly on date provided below.

Approval Date: 27-Mar-2020 GMT

**Medical Monitor Name and Contact Information will be provided separately.**

## Protocol Amendment Summary of Changes Table

<b>DOCUMENT HISTORY</b>	
<b>Document</b>	<b>Date</b>
Original Protocol	30 January 2020

### Amendment (a)

#### Overall Rationale for the Amendment:

This amendment addresses Food and Drug Administration (FDA) feedback.

<b>Section # and Name</b>	<b>Description of Change</b>	<b>Brief Rationale</b>
Section 1.3. Schedule of Activities	Addition of visit window for post-randomization visits	Allows flexibility for participants
Section 1.3. Schedule of Activities	Included details for vital signs and targeted physical examination	Per regulatory feedback
Section 1.3. Schedule of Activities	Included additional urine pregnancy sample collection and updated description of those who would be tested	Per new toxicology data
Section 1.3. Schedule of Activities	Included additional sample collection time for hemoglobin A1c	Sample collection time missed in the original version
Section 2.3.1. Risk Assessment	Removed language for women of childbearing potential and added language for fetal exposure	Women of childbearing potential are now allowed in the study; pregnant or breastfeeding women are not allowed
Section 4 Study Design	Amended post-treatment follow-up period instructions	Updated to maximize data collection in the follow-up period
Section 5.1. Inclusion Criteria	Removed criterion related to women not of childbearing potential	To account for the addition of women of childbearing potential to the study per toxicology data
Section 5.2. Exclusion Criteria	Addition of language related to ophthalmologic disease	Per regulatory feedback
Section 5.2. Exclusion Criteria	Removed criterion related to abnormal thyroid stimulating hormone levels	Covered by the master Protocol H0P-MC-CPMP
Section 5.2. Exclusion Criteria	Addition of criterion related to women who are pregnant or breastfeeding	Per regulatory feedback
Section 5.3. Lifestyle Considerations	Removed language about local regulations for contraception use by men	This language is intended for global studies. This study will be conducted in the United States only.
Section 6.1.1. Special Treatment Considerations	Addition of special treatment considerations	Per regulatory feedback
Section 8.1.1. Physical	New section to include details on targeted physical examination	Per regulatory feedback

<b>Section # and Name</b>	<b>Description of Change</b>	<b>Brief Rationale</b>
Examinations		
Section 10.2, Appendix 2	Addition of definitions and contraceptive guidance related to women of childbearing potential	To account for the addition of women of childbearing potential to the study per toxicology data
Throughout the protocol	Minor editorial and formatting changes	Minor, therefore not described

## Table of Contents

<b>1.</b>	<b>Protocol Summary .....</b>	<b>7</b>
1.1.	Synopsis .....	7
1.2.	Schema .....	9
1.3.	Schedule of Activities (SoA) .....	9
<b>2.</b>	<b>Introduction .....</b>	<b>13</b>
2.1.	Study Rationale .....	13
2.2.	Background .....	13
2.3.	Benefit/Risk Assessment .....	14
2.3.1.	Risk Assessment .....	15
2.3.2.	Benefit Assessment .....	16
2.3.3.	Overall Benefit: Risk Conclusion .....	16
<b>3.</b>	<b>Objectives and Endpoints.....</b>	<b>17</b>
<b>4.</b>	<b>Study Design .....</b>	<b>18</b>
4.1.	Scientific Rationale for Study Design .....	19
4.2.	Justification for Dose .....	19
4.3.	End of Study Definition .....	19
<b>5.</b>	<b>Study Population .....</b>	<b>20</b>
5.1.	Inclusion Criteria .....	20
5.2.	Exclusion Criteria .....	20
5.3.	Lifestyle Considerations .....	21
<b>6.</b>	<b>Study Intervention.....</b>	<b>22</b>
6.1.	Study Intervention(s) Administered .....	22
6.1.1.	Special Treatment Considerations .....	23
6.2.	Preparation/Handling/Storage/Accountability .....	24
6.3.	Measures to Minimize Bias: Randomization and Blinding .....	24
6.4.	Study Intervention Compliance .....	24
6.5.	Concomitant Therapy .....	24
<b>7.</b>	<b>Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal.....</b>	<b>25</b>
7.1.	Discontinuation of Study Intervention .....	25
<b>8.</b>	<b>Study Assessments and Procedures .....</b>	<b>26</b>
8.1.	Safety Assessments .....	26
8.1.1.	Physical Examinations .....	26
8.1.2.	Electrocardiograms .....	26
8.1.3.	Clinical Safety Laboratory Assessments .....	26
8.2.	Adverse Events and Serious Adverse Events .....	26
8.2.1.	Infusion Site Reactions .....	26
8.2.2.	Hypersensitivity Reactions and Infusion-related Reactions .....	26
8.2.3.	Adverse Events of Special Interest .....	28
8.3.	Treatment of Overdose .....	28
8.4.	Pharmacokinetics .....	28

8.5. Pharmacodynamics ..... 29

8.6. CCI ..... 29

8.7. Immunogenicity Assessments ..... 29

**9. Statistical Considerations ..... 30**

9.1. Statistical Hypotheses ..... 30

9.2. Sample Size Determination ..... 30

9.3. Populations for Analyses ..... 30

9.4. Statistical Analyses ..... 30

9.4.1. General considerations ..... 30

9.4.2. Other Analyses ..... 31

9.5. Interim Analyses ..... 31

**10. Supporting Documentation and Operational Considerations ..... 32**

10.1. Appendix 1: Clinical Laboratory Tests ..... 32

10.2. Appendix 2: Definitions of Reproductive Requirements and  
Contraceptive Guidance ..... 33

10.3. Appendix 3: Recommended Laboratory Testing for  
Hypersensitivity Events and Infusion-related Reactions ..... 35

**11. References ..... 36**

## **1. Protocol Summary**

### **1.1. Synopsis**

#### **Protocol Title:**

Randomized, placebo-controlled, Phase 2 clinical trial to evaluate LY3016859 for the treatment of diabetic peripheral neuropathic pain.

#### **Rationale:**

The purpose of this study is to test whether LY3016859 is efficacious in relieving diabetic peripheral neuropathic pain (DPNP). LY3016859 is a high affinity humanized immunoglobulin G (IgG)<sub>4</sub> monoclonal antibody that binds to key residues in the C-terminal regions of transforming growth factor- $\alpha$  (TGF- $\alpha$ ) and epiregulin, preventing their binding to the epidermal growth factor receptor (EGFR).

Data will be collected to assess the safety and tolerability of LY3016859 in this study population. Pharmacokinetic (PK) properties, pharmacodynamic (PD) effects and immunogenicity profile will also be explored. The totality of data from this proof-of-concept study will assess the benefits and risks associated with LY3016859 and inform decisions for the clinical development of LY3016859.

#### **Objectives and Endpoints**

The primary and secondary objectives and endpoints are stated in the master protocol H0P-MC-CPMP (CPMP) and DPNP disease-state addendum ([DSA] H0P-MC-CPMP[3]).

#### **Overall Design:**

This is a 26-week, Phase 2, randomized, double-blind, placebo-controlled study that will compare LY3016859 versus placebo in participants with DPNP.

**Disclosure Statement:** This is a randomized, investigator- and participant-blind, placebo-controlled, Phase 2 clinical trial.

#### **Number of Participants:**

Approximately 125 participants will be randomly assigned to study intervention (84 LY3016859 and 41 placebo) with the assumption that 15% of the participants will drop out prior to the end of the double-blind treatment period.

#### **Intervention Groups and Duration:**

This 26-week study includes an 8-week double-blind treatment period and an 18-week follow-up period.


Participants will receive an intravenous (IV) infusion every 2 weeks for a total of 4 infusions.

<b>Intervention Name</b>	LY3016859	Placebo
<b>Dosage Level(s)</b>	750 mg starting dose 500 mg subsequent doses	Not applicable
<b>Route of Administration and duration</b>	1 hour IV infusion	1 hour IV infusion

Participants will be monitored for at least 4 hours after completion of the infusion.

**Data Monitoring Committee: Yes**

### 1.2. Schema




\* Medication washout and preliminary data entry period begins.  
 \*\* Randomization to either LY3016859 or placebo.  
 † Each participant receives a 1 hour infusion at Visits 3, 4, 5, and 6.  
 Abbreviations: IV = intravenous; PDEP = preliminary data entry period; V = visit.

### 1.3. Schedule of Activities (SoA)

This SoA shows visits and procedures unique to the intervention-specific appendix (ISA) H0P-MC-NP01 (NP01) for LY3016859. Please refer to master protocol H0P-MC-CPMP (CPMP) and the diabetic peripheral neuropathic pain (DPNP) disease-state addendum (DSA) H0P-MC-CPMP(3) SoAs for additional information.

H0P-MC-NP01 ISA	Randomization	Double-Blind Treatment				Follow-up			Early Discontinuation	Notes
Visit Number	V3	V4	V5	V6	V7	V801	V802	V803	ED	
Study Week	0	2	4	6	8	12	16	26		
Visit Window (days)		±3	±3	±3	±3	±5	±7	±7		Minimal interval between 2 doses cannot be shorter than 11 days.
Physical examination	X	X	X	X	X	X	X	X	X	Targeted exam for skin, eyes, mouth, lungs and GI tract should be performed at each visit, in addition to any symptom driven exam. Full physical exam should be performed at Visit 803 or ED.
Weight								X		
Vital signs	X	X	X	X	X	X	X	X		Includes respiratory rate, blood pressure, temperature and pulse rate. All vital signs are collected before study intervention infusion on V3-6.
ECG			X		X			X		Single safety ECGs
Study Intervention IV infusion	X	X	X	X						1 hour IV administration The timing between randomization and the first IV infusion may be up to, but not longer than 2 business days to reduce participant burden.
Adverse Events						X	X	X		
Concomitant medication						X	X	X		
Rescue medication usage reporting						X				If the participant discontinues after V801, this assessment is not needed for ED per the CPMP SoA.
NRS						X				If the participant discontinues after V801, this assessment is not needed for ED per the CPMP SoA.
PGI						X				If the participant discontinues after V801, this assessment is not needed for ED per the CPMP SoA.

H0P-MC-NP01 ISA	Randomization	Double-Blind Treatment				Follow-up			Early Discontinuation	Notes
Visit Number	V3	V4	V5	V6	V7	V801	V802	V803	ED	
Study Week	0	2	4	6	8	12	16	26		
Visit Window (days)		±3	±3	±3	±3	±5	±7	±7		Minimal interval between 2 doses cannot be shorter than 11 days.
BPI						X				If the participant discontinues after V801, this assessment is not needed for ED per the CPMP SoA.
C-SSRS						X		X		Use C-SSRS Since Last Visit version.
Self-Harm Supplement Form						X		X		
Self-Harm Follow-up Form						X		X		Required if triggered by the Self-Harm Supplement Form per instructions.
Hematology						X	X	X		
Chemistry		X		X		X	X	X		
Urine Chemistries	X	X	X	X	X	X		X	X	
Urinalysis								X		
Urine pregnancy	X	X	X	X	X			X	X	For all premenopausal females or postmenopausal females <50 years of age V3: collect sample before randomization
Urine drug screen	X		X		X					
Hemoglobin A1c	X				X			X	X	

H0P-MC-NP01 ISA	Randomization	Double-Blind Treatment				Follow-up			Early Discontinuation	Notes
Visit Number	V3	V4	V5	V6	V7	V801	V802	V803	ED	
Study Week	0	2	4	6	8	12	16	26		
Visit Window (days)		±3	±3	±3	±3	±5	±7	±7		Minimal interval between 2 doses cannot be shorter than 11 days.
PK sample	X	X	X	X	X	X	X	X	X	V3-6: collect samples before IV infusion starts and within 15 minutes after IV infusion is complete. V7 – V803: single sample collected at any time. Obtain PK samples from opposite arm used for IV infusion. Record date and time of collection.
Immunogenicity (ADA) sample	X	X	X		X	X		X	X	V3-6: collect sample before IV infusion starts
Epiregulin sample	X	X	X		X	X	X	X	X	V3-6: collect samples before IV infusion starts. V7-V803: single sample collected at any time to match PK.
										

Abbreviations: ADA = anti-drug antibody; BPI = Brief pain inventory-modified short form; C-SSRS = Columbia Suicidal Severity Rating Scale; ECG = electrocardiogram; GI = gastrointestinal; IV = intravenous; NRS = Numeric Rating Scale for pain; PGI = Patient Global Impression of Change; PK = pharmacokinetic; V = visit.

## 2. Introduction

This ISA NP01 is an appendix to the master protocol CPMP and contains unique study elements specific for LY3016859. The master protocol contains the overarching study elements that govern the DPNP DSA CPMP(3) and this ISA NP01.

LY3016859 is a high affinity humanized immunoglobulin G (IgG)<sub>4</sub> monoclonal antibody that binds to key residues in the C-terminal regions of transforming growth factor- $\alpha$  (TGF- $\alpha$ ) and epiregulin, preventing their binding to the epidermal growth factor receptor (EGFR). Engagement of LY3016859 results in internalization of the membrane-spanning ligands and neutralization of mature ligand activity *in vitro*.

The EGFR and epiregulin are associated with pain processing (Martin et al. 2017). Epiregulin is increased in blood after nerve injury/insult (Martin et al. 2017). Inhibition of EGFR with clinically available compounds strongly reduces nocifensive behavior in mouse models of inflammatory and chronic pain, including spinal nerve injury and chronic constriction injury (Martin et al. 2017).

Non-controlled reports show that EGFR inhibition by various oncologic drugs provides rapid relief of pain (Kersten et al. 2013; Kersten et al. 2015; Juhasz et al. 2013); and the pain relief was independent of disease progression (Kersten and Cameron 2012).

### 2.1. Study Rationale

The purpose of this study is to test whether LY3016859 is efficacious in relieving DPNP. Data will be collected to assess the safety, and tolerability of LY3016859 in this study population. Pharmacokinetic (PK) properties, pharmacodynamic (PD) effects and immunogenicity profile will also be explored. The totality of data from this proof-of concept study will assess the benefits and risks associated with LY3016859 and inform decisions for the clinical development of LY3016859.

### 2.2. Background

LY3016859 was initially developed for the treatment of diabetic nephropathy and 2 clinical studies were completed.

<b>Study</b>	I5V-MC-TGAA (TGAA)
<b>Population</b>	Healthy participants
<b>Study Design</b>	Placebo-controlled, randomized, single-dose escalation
<b>LY3016859 Dose</b>	Intravenous (IV) infusion and subcutaneous: 0.1, 1, 10, 50, 250, and 750 mg
<b>Objectives</b>	Evaluate safety, tolerability, and pharmacokinetics after single IV and subcutaneous dosing.

<b>Study</b>	I5V-MC-TGAB (TGAB)
<b>Population</b>	Participants with diabetic nephropathy
<b>Study Design</b>	2-part, placebo-controlled, randomized, multiple dose escalation and parallel dose study
<b>LY3016859 Dose</b>	Part A: dose range of 10 to 750 mg, administered as a 60-minute IV infusion once every 3 weeks for a total of 2 doses  Part B: 60-minute IV infusion once every 3 weeks up to 5 doses, if tolerated Doses did not exceed the maximum tolerated dose from Part A.
<b>Objectives</b>	Evaluate safety, tolerability, and pharmacokinetics and pharmacodynamics. Change from baseline in proteinuria at 16 weeks.

### Pharmacokinetics

LY3016859 serum concentration increased more than proportionally with dose; and the terminal half-life increased with dose (approaching 18 days at higher doses), consistent with target-mediated drug disposition.

### Pharmacodynamics

LY3016859 demonstrated dose-related target engagement for both TGF- $\alpha$  and epiregulin.

### Safety

Intravenous doses of up to 750 mg LY3016859 were safe and reasonably well tolerated.

A detailed description of the chemistry, pharmacology, efficacy, and safety of LY3016859 is provided in the Investigator's Brochure (IB).

## 2.3. Benefit/Risk Assessment

The IB provides detailed information about the known and expected benefits and risks, and reasonably expected adverse events (AEs) of LY3016859.

**2.3.1. Risk Assessment**

Potential Risk of Clinical Significance	Summary of Data/Rationale for Risk	Mitigation Strategy
<b>Study Intervention LY3016859</b>		
Development of treatment-emergent anti-drug antibodies (TE ADA).	Incidence of TE ADA was 50% after a single dose, and up to 57% after multiple doses.	Collect samples up to 20 weeks after last dose to characterize ADA profile.
IV infusion may be associated with infusion reactions and hypersensitivity reactions.	LY3016859 is a monoclonal antibody that will be administered via IV infusion. Hypersensitivity reactions and infusion reactions may occur during treatment with such agents.	Monitor infusion reactions and hypersensitivity reactions. Guidance on management of infusion and hypersensitivity reactions are in Sections 8.2.1. and 8.2.2.
Dermatological adverse reactions similar to EGFR antagonists	One healthy participant who received a single dose of 1 mg LY3016859 experienced a rash that was considered similar to those associated with EGFR antagonists.	Collect dermatological AEs. Stop dosing for severe dermatological AEs.
Changes in eGFR in participants with diabetic nephropathy (DN)	A modest and non-statistically significant decrease in eGFR was observed in participants with DN who received LY3016859 in Part B of Study TGAB, but not in healthy participants in Study TGAA.	Exclude participants with moderate renal impairment in the study. Monitor eGFR and stop dosing if necessary. CCI [REDACTED]
Fetal harm due to in utero exposure	No effects on embryo-fetal development in enhanced pilot embryo-fetal development studies in rats and rabbits. Definitive developmental and reproductive toxicity studies are not yet completed.	Do not enroll women who are pregnant or breastfeeding in studies for LY3016859.
<b>Study Procedures</b>		
Participant may experience increased pain symptoms.	Medications other than those permitted per protocol will not be allowed until Visit 801.	Rescue medication is permitted. Standard treatment of pain may be restarted after Visit 801 based on investigator discretion.

Abbreviations: ADA = anti-drug antibodies; AE = adverse events; DN = diabetic nephropathy; EGFR = epidermal growth factor receptor; eGFR = estimated glomerular filtration rate; IV = intravenous; TE = treatment emergent; TGAA = study I5V-MC-TGAA; TGAB = study I5V-MC-TGAB.

### **2.3.2. Benefit Assessment**

Potential benefits for the study participants include

- study-related medical procedures
  - physical examinations,
  - laboratory tests
  - electrocardiograms (ECGs)
- detailed evaluations of diabetic nerve pain
- questionnaires that may improve participants understanding their own condition.

As part of Study CPMP, participants to this ISA will report their experience using standard tools that will contribute to the assessment of novel treatments for DPNP. In addition, data collected from this study may also improve our understanding of DPNP pathogenesis. Both of which may lead to the development of new treatment with improved safety and efficacy profile compared to standard of care.

### **2.3.3. Overall Benefit: Risk Conclusion**

The measures taken to minimize risk to participants in this study and the potential risks identified in association with ISA NP01 are justified by the anticipated benefits to participants with DPNP.

### 3. Objectives and Endpoints

The master protocol CPMP and DPNP DSA CPMP(3) include objectives and endpoints applicable for this study. This table describes objectives and endpoints specific for LY3016859.

Objectives	Endpoints
<b>Tertiary/Exploratory</b>	
Characterize the pharmacokinetics and pharmacodynamics of LY3016859 after multiple intravenous infusions in participants with diabetic peripheral neuropathic pain	Assessment of serum concentrations of LY3016859 and epiregulin to enable pharmacokinetic and pharmacodynamic evaluations
Characterize immunogenicity of LY3016859	Appearance of anti-drug antibodies and neutralizing antibodies to LY3016859
Explore the effect of LY3016859 on the kidney	Assessment of <ul style="list-style-type: none"> <li>• urine albumin/creatinine ratio</li> <li>• urine protein/creatinine ratio</li> <li>• eGFR</li> </ul>

Abbreviations: eGFR = estimated glomerular filtration rate.

#### 4. Study Design

Protocol CPMP describes the overall study design and study design rationale. This section describes visits and overall procedures unique to ISA NP01 for LY3016859 in addition to the procedures outlined in CPMP and CPMP(3).

##### **Double-blind Treatment Period (Visits 3 through 7)**

Each visit is an outpatient visit.

At Visit 3

- participants are randomized to LY3016859 or placebo
- the site completes the NP01 baseline procedures and sample collection
- participants receive their first dose of study intervention via IV infusion over 1 hour
- the site observes participants in the clinic for at least 4 hours after the completion of the IV infusion
- the site completes all post-treatment sample collection and safety monitoring, and
- the site instructs participants to continue with study restrictions and Numeric Rating Scale (NRS) diary entries before their visit discharge.

At Visits 4 through 6

- the site reviews available safety data and completes pre-dose procedures and sample collection
- participants receive an IV infusion over 1 hour
- the site observes participants in the clinic for at least 4 hours after the completion of the IV infusion
- the site completes all post-treatment sample collection and safety monitoring, and
- the site instructs participants to continue with study restrictions and NRS diary entries before their visit discharge.

At Visit 7

- the site completes all procedures and sample collection noted in the SoAs
- no intervention is administered at this visit, and
- the site instructs participants to continue with study restrictions and NRS diary entries before their visit discharge.

##### **Post-treatment Follow-up Period (Visits 801-803)**

Participants must complete 3 post-treatment follow-up visits for safety, PK and immunogenicity assessment at Visits 801-803, according to the SoA.

The site schedules Visit 801 approximately 4 weeks after Visit 7.

At Visit 801, participants return the device for NRS diary collection.

At Visit 803, the participants are discharged from the study.

If the participant receives at least one dose of intervention and discontinues during the double-blind treatment period, they should complete early discontinuation procedures per the CPMP protocol SoA and Visit 801 should be scheduled approximately 30 days after the last dose of study intervention.

#### **4.1. Scientific Rationale for Study Design**

The master protocol describes the overall study design rationale.

Efficacy data will be collected up to 6 weeks after the last dose, based on the long PK half-life and potential sustained target engagement of LY3016859.

Safety, PK, PD and immunogenicity samples will be collected up to 20 weeks after the last administration of intervention to characterize the safety and clinical immunogenicity profile.

#### **4.2. Justification for Dose**

The proposed dose for proof-of-concept is a 750-mg starting dose followed by 500 mg every 2 weeks IV for a total of 4 doses. The dose level and duration are based on the available toxicology, safety, PK and PD data from the completed studies detailed in the LY3016859 Investigator's Brochure.

Briefly, the proposed dose regimen maintains an approximate 10-fold margin of safety (MOS) relative to the no-observed-adverse-effect level (NOAEL) for both rat and monkey repeated dose toxicology studies (Table 4.5 in the IB) and is expected to achieve steady state exposure similar to the 750 mg every 3 weeks dosing regimen tested in Study TGAB. The safety data from the completed TGAA and TGAB studies, and the clinical management plan support testing the proposed dose regimen in participants with various chronic pain conditions.

The PK analyses show a similar PK profile for LY3016859 in healthy participants and patients with various degrees of renal impairment, which is expected for a monoclonal antibody.

While the degree of target-engagement required for analgesic efficacy for LY3016859 has not been established in the clinic, the proposed dosing regimen is expected to reach steady-state within a month CCI

. If the epiregulin blockade is beneficial for DPNP, then this level of target engagement is expected to enable analgesic efficacy.

#### **4.3. End of Study Definition**

A participant is considered to have completed this ISA if he or she has completed all required phases of the study including the last scheduled procedure shown in the ISA Schedule of Activities.

The end of the study is defined as the date of the last visit of the last participant in the study or last scheduled procedure shown in the ISA Schedule of Activities for the last participant.

## 5. Study Population

The master protocol CPMP and DPNP DSA CPMP(3) provide eligibility criteria that must be followed for this study. LY3016859 specific inclusion and exclusion criteria are listed here.

### 5.1. Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

- [3000] are men or women who abide by the reproductive and contraceptive requirements provided in NP01 Section 10.2, Appendix 2
- [3001] are willing to discontinue all pain medications for condition under study except rescue medication permitted per protocol until V801 in the follow-up period
- [3002] must have venous access in both arms for IV infusion and sample collection.

### 5.2. Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

#### Medical Conditions

- [3003] Have an eGFR of less than 70 ml/min/1.73m<sup>2</sup> based on CKD-EPI formula at Visit 1 or Visit 2
- [3004] Have any clinically serious or unstable cardiovascular, musculoskeletal disorder, gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic, pulmonary, dermatologic, immunologic, or ophthalmologic disease within 3 months of Visit 3
- [3005] have megaloblastic anemia or combined degeneration of the spinal cord

#### Prior/Concomitant Therapy

- [3006] have received any antibodies against nerve growth factor (NGF), or antibodies against EGFR, or EGFR tyrosine kinase inhibitors.
- [3007] have a history of allergic reactions to monoclonal antibodies, or clinically significant multiple or severe drug allergies, including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis.
- [3008] have a history or presence of uncontrolled asthma, eczema, significant atopy, significant hereditary angio-edema or common variable immune deficiency, and

#### Reproductive

- [3009] are women who are pregnant or breastfeeding.

### **5.3. Lifestyle Considerations**

#### **Reproductive and Contraception Requirements**

Reproductive requirements and contraceptive guidance are provided in NP01 Appendix 2, Section [10.2](#).

#### **Caffeine and Alcohol**

Participants should maintain their usual caffeine intake.

Participants should limit their alcohol consumption for the duration of the study.

Men up to the age of 65 should not exceed an average weekly alcohol intake of 21 units per week.

Men over the age of 65 and women should not exceed an average weekly alcohol intake of 14 units per week.

One unit of alcohol equals

- 12 oz or 360 mL of beer
- 5 oz or 150 mL of wine, or
- 1.5 oz or 45 mL of distilled spirits.

#### **Diet and Activities**

Participants are required to maintain a similar diet and levels of activity during the double-blind study period. Starting a new diet or exercise program or new strenuous activity is not allowed.

#### **Exposure to Sun**

Participants should use sun protection and avoid sunbathing and use of sun beds for the duration of the study. Sun protection may consist of protective clothing or SPF 50 lotion.

## 6. Study Intervention

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

### 6.1. Study Intervention(s) Administered

The study intervention will be administered via a slow IV infusion over approximately 1 hour by blinded site personnel. The infusion rate may be reduced as deemed necessary if an infusion reaction is observed. Participants will be monitored for at least 4 hours after completion of each infusion. Site must have resuscitation equipment, emergency drugs and appropriately training staff available during the infusion and for at least 4 hours after the completion of the infusion. Participants should not use tobacco products from 1 hour before the start of dosing until after collection of the final PK or PD sample after dosing.

<b>Intervention Name</b>	LY3016859	Placebo
<b>Type</b>	Biologic	Not applicable
<b>Dose Formulation</b>	Lyophilized powder reconstituted with sterile water	0.9% Sodium chloride solution
<b>Unit Dose Strength(s)</b>	75 mg/vial	Not applicable
<b>Dosage Level(s)</b>	750 mg starting dose 500 mg subsequent doses	Not applicable
<b>Route of Administration</b>	1 hour IV infusion	1 hour IV infusion
<b>Use</b>	experimental	placebo
<b>IMP and NIMP</b>	IMP and NIMP	IMP and NIMP
<b>Sourcing</b>	LY3016859 from Lilly If needed, saline for reconstitution of IMP will be site sourced	Placebo will be procured, packaged, labeled, distributed and dispensed as IMP by Lilly
<b>Packaging and Labeling</b>	The lyophilized powder and sterile diluent for infusion will be provided in separate glass vials. Each vial will be labeled as required per country requirement	Placebo will be provided in a glass vial. Each vial will be labeled as required per country requirement

Abbreviations: IMP = investigational medicinal product; NIMP = non-investigational medicinal product.

### 6.1.1. Special Treatment Considerations

#### 6.1.1.1. Premedication for Infusions

Premedication for infusions is not planned. However, if an infusion reaction occurs, the study investigator(s) should determine the appropriate premedication for subsequent infusions for that participant.

The investigators and sponsor may decide to use premedication for all participants. They will decide this if the frequency of infusion reactions among participants warrants it.

Any premedications given will be documented as a concomitant therapy (see Section 6.5).

#### 6.1.1.2. Management of Infusion Reactions

All participants should be monitored closely, as there is a risk of infusion reaction and hypersensitivity (including anaphylaxis) with any biological agent.

##### Symptoms and Signs

Symptoms and signs that may occur as part of an infusion reaction include, but are not limited to fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash, pruritus, myalgia, and dizziness.

##### Site Needs

The clinical site should have necessary equipment and medications for the management of any infusion reaction, which may include but is not limited to oxygen, IV fluid, epinephrine, acetaminophen and antihistamine.

##### Management of Infusion Reactions

Investigators should grade the severity of the infusion reaction and manage infusion reactions based on standard of care and their clinical judgment. If an infusion reaction occurs, then supportive care should be used in accordance with the signs and symptoms.

This table outlines guidance when a mild to moderate infusion reaction occurs.

<b>If...</b>	<b>Then...</b>
a mild to moderate infusion reaction occurs	the infusion rate should be slowed or stopped depending on the symptoms or signs present. For example, reducing the rate by 50% from 2 mL/minute to 1 mL/minute.
the infusion rate is slowed	<ul style="list-style-type: none"> <li>the infusion should be completed at the slower rate, as tolerated.</li> <li>subsequent infusions may be administered at the discretion of the investigator in agreement with the Lilly medical monitor.</li> </ul>
the infusion rate is slowed, and subsequent infusions are continued	the infusion rate must be maintained at the slowest tolerated rate used.

The study intervention infusion should be stopped immediately and permanently if it is an infusion reaction

- with systemic involvement, including, but not limited to significant treatment emergent hypotension, bronchospasm, or wide-spread urticaria
- that does not respond to a slower infusion rate or oral medications
- that is determined as clinically significant by the investigator.

If a participant permanently discontinues from study intervention, they should complete AE monitoring and other procedures as stated in Section 4, Study Design, and the CPMP and NP01 SoAs.

## **6.2. Preparation/Handling/Storage/Accountability**

Study intervention and placebo require refrigeration.

Study intervention and placebo will be prepared and verified by unblinded site personnel.

## **6.3. Measures to Minimize Bias: Randomization and Blinding**

### **Stratification Variables**

Estimated GFR will be used for stratification to ensure a balanced number of participants for analysis of renal effects. Measurements will be collected at Visit 2 and the subsets are

- greater than or equal to 90, and
- less than 90.

## **6.4. Study Intervention Compliance**

Participants will receive study intervention directly from the investigator or designee, under medical supervision. The date and time of each study intervention administered in the clinic will be recorded in the source documents and case report form (CRF). Administration of intervention and study participant identification will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention.

## **6.5. Concomitant Therapy**

All concomitant therapies that are part of routine care for other comorbidities besides DPNP, are allowed and can be used during the study, if it is permitted based on the inclusion and exclusion criteria.

A list of medications that are prohibited from Visit 2 to Visit 801 for participants randomized to this ISA study will be provided. Participants may return to their standard-of-care after Visit 801 is completed, as clinically appropriate.

## **7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal**

Protocol CPMP provides the reasons and procedures for discontinuation of intervention and participant discontinuation that must be followed for this study. LY3016859 specific information is included here.

### **7.1. Discontinuation of Study Intervention**

If the investigator, after consultation with the sponsor-designated medical monitor, determines that a systemic hypersensitivity reaction or a serious infusion reaction has occurred related to study intervention administration, the participant should be permanently discontinued from the study intervention.

A participant should be discontinued from study intervention if they experience a dermatological adverse reaction, such as acneiform rash, that is related to study intervention, **and** is either mild to moderate and does not respond to topical treatment **or** is severe. The participant may continue in the study at the discretion of the investigator in consultation with the medical monitor or study sponsor physician/scientist.

## **8. Study Assessments and Procedures**

Study procedures and their timing are summarized in the protocol CPMP, DPNP DSA CPMP(3), and ISA NP01 SoAs.

LY3016859 specific assessments and procedures are described here.

### **8.1. Safety Assessments**

Planned time points for all safety assessments are provided in the SoA.

#### **8.1.1. Physical Examinations**

Targeted physical examinations of skin, eyes, mouth, lungs and GI tract will be performed at each visit as described in the SoA. Any clinically significant abnormal physical examination findings will be reported as AEs.

#### **8.1.2. Electrocardiograms**

Single 12-lead ECG will be obtained as outlined in the SoA using an ECG machine that automatically calculates the heart rate and measures pulse rate, QRS, QT, and QTc.

#### **8.1.3. Clinical Safety Laboratory Assessments**

See NP01 Appendix 1 (Section 10.1) for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency for ISA NP01.

## **8.2. Adverse Events and Serious Adverse Events**

### **8.2.1. Infusion Site Reactions**

Symptoms of a local infusion site reaction may include erythema, induration, pain, pruritus, and edema. If an infusion site event is reported, the AE will be recorded, and additional data will be provided to the sponsor in the CRF.

Additional blood and urine samples should be collected as described in NP01 Section 10.3, Appendix 3, "Recommended Laboratory Testing for Hypersensitivity Events". Laboratory results are provided to the sponsor via the central laboratory.

### **8.2.2. Hypersensitivity Reactions and Infusion-related Reactions**

Many drugs, but particularly biologic agents, carry the risk of systemic hypersensitivity reactions. Drugs administered via IV infusion may lead to a systemic infusion-related reaction. If such a reaction occurs, additional data describing each symptom should be provided to the sponsor in the CRF.

Sites should have appropriately trained medical staff and appropriate medical equipment available when study participants are receiving study intervention. It is recommended that participants who experience a systemic reaction be treated per the local standard of care.

In the case of generalized urticaria or anaphylaxis, or moderate to severe infusion-related reactions, additional blood and urine samples should be collected as described in NP01

Section 10.3, Appendix 3, “Recommended Laboratory Testing for Hypersensitivity Events”.  
Laboratory results are provided to the sponsor via the central laboratory.

### 8.2.3. Adverse Events of Special Interest

#### Dermatological adverse reactions

EGFR antibodies or EGFR-associated tyrosine kinase inhibitors are associated with various dermatological AEs, including acneiform rashes, xerosis, pruritis, and photosensitivity.

Secondary infection can also develop.

Participants should use sun protection for the duration of the study. Dermatological adverse reactions should be managed by the investigator according to standard of care. Discontinuation of treatment may be considered if these AEs do not respond to topical treatment or are widespread (>30% body surface area) or are severe.

If any of these AEs are reported, sites will be prompted to provide additional information.

#### Renal Function

Changes in eGFR were observed in participants with diabetic nephropathy in study TGAB (Section 2.2). Such changes were reversible and were not associated with increase in proteinuria. Blood and urine samples will be collected to characterize the effects of LY3016859 on renal function and eGFR will be monitored during the study.

### 8.3. Treatment of Overdose

In case of suspected overdose, participants should be monitored for any signs or symptoms of adverse reactions or effects, and supportive care should be provided as necessary.

### 8.4. Pharmacokinetics

Venous blood samples of approximately 4 mL will be collected for measurement of LY3016859 concentrations as specified in the SoA. Samples will be used to evaluate the PK of LY3016859.

A maximum of 3 samples may be collected at additional time points during the study if warranted and agreed upon between the investigator and the sponsor.

Instructions for the collection and handling of biological samples will be provided by Lilly.

Site personnel will record

- The date and time (24-hour clock time) of LY3016859 administration (start and end of infusion), and
- The date and time (24-hour clock time) of each PK sample.


It is essential that the times are recorded accurately.

Pharmacokinetic samples will be retained for a maximum of 2 years following last subject visit for the study. CCI

## 8.5. Pharmacodynamics

Venous blood samples of approximately 4 mL each will be collected for the measurement epiregulin as specified in the SoA. Any remaining blood samples may be used to test other potential PD endpoints, including, but not limited to TGF- $\alpha$ .

Instructions for the collection and handling of biological samples will be provided by Lilly.



## 8.7. Immunogenicity Assessments

### Visits and times

At the visits and times specified in the SoA, predose venous blood samples will be collected to determine antibody production against LY3016859. The actual date and time (24-hour clock time) of each sample collection will be recorded.

If the immunogenicity sample at the last scheduled assessment or discontinuation visit is treatment-emergent (TE) anti-drug antibody (ADA) positive (as defined in Section 9.4.2.1), additional samples may be taken until the signal returns to baseline (i.e., no longer TE-ADA positive) or for up to 1 year after last dose.

To aid interpretation of these results, a predose blood sample for PK analysis will be collected at the same time points.

### Sample collection, handling, and use

Instructions for the collection and handling of blood samples will be provided by the sponsor.

Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence of LY3016859 at a laboratory approved by the sponsor. Antibodies may be further characterized for their ability to neutralize the activity of LY3016859.

### Sample retention

Sample retention is described in protocol CPMP, Appendix 1, Section 10.1.12.

## 9. Statistical Considerations

The master protocol and DPNP DSA provide statistical considerations. LY3016859 specific considerations are described here.

### 9.1. Statistical Hypotheses

The master protocol CPMP describes the primary hypothesis. CCI [REDACTED]

### 9.2. Sample Size Determination

Approximately 125 participants will be randomized in a CCI ratio to LY3016859 and placebo, respectively. It is expected that approximately 107 participants will complete the double-blind treatment period of the study. CCI [REDACTED]

CCI [REDACTED]

If there is no treatment difference between placebo and LY3016859, the probability of passing the efficacy criterion specified above (i.e., false positive) is approximately 0.06. The simulation for the power calculation and sample size determination was carried out in FACTS Version 6.0.

### 9.3. Populations for Analyses

The populations are defined in protocol CPMP.

The pharmacokinetic population includes all randomized participants who received a full dose of LY3016859 at Visit 3 and have at least 1 evaluable PK sample collected prior to dosing at or after Visit 4.

### 9.4. Statistical Analyses

Any change to the data analysis methods described in this ISA will require an amendment only if it changes a principal feature of the ISA. Any other change to the data analysis methods described, and the justification for making the change, will be described in the statistical analysis plan (SAP) and the clinical study report. Additional exploratory analyses of the data will be conducted as deemed appropriate.

The ISA SAP will be finalized prior to unblinding, and it will include a more technical and detailed description of the statistical analyses described in this section.

#### 9.4.1. General considerations

The primary endpoint and analyses have been described in protocol CPMP.

Any borrowing of placebo or treatment effect information will be specified in the ISA SAP. Secondary and Tertiary/Exploratory endpoints and analyses are described in protocol CPMP and DSA CPMP(3).

#### **9.4.2. Other Analyses**

##### **9.4.2.1. Immunogenicity**

Treatment-emergent ADAs are defined as participants

- with a 2-fold (1 dilution) increase in titer than the minimum required dilution if no ADAs were detected at baseline (treatment-induced ADA) or
- with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected at baseline (treatment-boosted ADA).

The frequency and percentage of participants with preexisting ADA and who are TE-ADA positive (TE-ADA+) to LY3016859 will be tabulated.

If neutralizing antibodies are assessed, the distribution of titers and frequency of neutralizing antibodies for the TE-ADA+ participants may also be tabulated.

The relationship between the presence of antibodies and PK parameters, PD response, safety or efficacy to LY3016859, may also be assessed. Additional details may be provided in the SAP.

##### **9.4.2.2. Pharmacokinetic and Pharmacodynamic Analyses**

Pharmacokinetic and pharmacokinetic-pharmacodynamic (PKPD) analyses may be conducted to explore the exposure-response relationships for various pharmacodynamics measures. The analyses will be performed using population analysis software, NONMEM, if data allows. The version of any software used for the analysis will be documented, and the program will meet the Lilly requirements of software validation. It is possible that other validated, equivalent PK software programs may be used if appropriate, warranted, and approved by Global PKPD management. Data may be pooled with data from other studies for an integrated PKPD analysis. The observed serum concentrations for LY3016859 and epipegulin will be reported graphically and descriptively.

A limited number of pre-identified individuals independent of the study team may receive access to unblinded data, as specified in the unblinding plan, prior to the interim or final database lock, in order to initiate the final population PKPD model development processes. Information that may unblind the study during the analyses will not be reported to study sites or blinded study team until the study has been unblinded.

#### **9.5. Interim Analyses**

An interim analysis may be conducted to plan for internal decision making. Unblinding details would be specified in the unblinding plan section of the SAP or in a separate unblinding document. The SAP will describe any interim analyses in greater detail should they occur.

## 10. Supporting Documentation and Operational Considerations

### 10.1. Appendix 1: Clinical Laboratory Tests

The master protocol CPMP describes tests that may be performed at additional times noted in the SoA for this ISA. This table describes tests unique for ISA NP01.

Chemistry	Urine Chemistries	Other Tests
Cystatin-C	Albumin	Immunogenicity
	Creatinine	Epiregulin
	Albumin/creatinine ratio (ACR)	LY3016859 concentration
	Protein	Urine pregnancy
	Protein/creatinine ratio (PCR)	

Refer to Section [10.3](#), Appendix 3 for recommended laboratory testing for hypersensitivity events.



## **10.2. Appendix 2: Definitions of Reproductive Requirements and Contraceptive Guidance**

### **Women**

Women of child-bearing potential may participate in this study.

Women of child-bearing potential must test negative for pregnancy prior to initiation of treatment as indicated by a negative serum pregnancy test at the screening visit followed by a negative urine pregnancy test within 24 hours prior to exposure.

Women of child-bearing potential who are completely abstinent or in a same sex relationship, as part of their preferred and usual lifestyle, must agree to either remain abstinent or stay in a same sex relationship without sexual relationships with males.

All other women of child-bearing potential must agree to use two forms of effective contraception, where at least one form is highly effective (less than 1% failure rate), for the entirety of the study.

Abstinence or contraception must continue for 90 days after the last dose of intervention.

### **Acceptable Methods of Contraception**

Highly effective methods of contraception (less than 1% failure rate) comprise, but are not limited to

- combination oral contraceptives
- implanted contraceptives, or
- intrauterine devices.

Effective methods of contraception comprise but are not limited to diaphragms with spermicide or cervical sponges.

### **Not Acceptable Methods of Contraception**

Use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined.

Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception.

Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.

Women not of childbearing potential may participate and include those who

- have a congenital anomaly such as Mullerian agenesis
- are infertile due to surgical sterilization, or
- are post-menopausal.

Surgical sterilization examples include

- hysterectomy

- bilateral oophorectomy, or
- tubal ligation.

At least 6 weeks must have passed after surgical bilateral oophorectomy with or without hysterectomy, or after tubal ligation.

Post-menopausal is defined as either

- a woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone >40 mIU/mL
- a woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea, or
- a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.

## **Men**

Men, regardless of their fertility status, must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms as well as one additional highly effective method of contraception (less than 1% failure rate) or effective method of contraception with non-pregnant women of child bearing potential partners for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 6 months after the last dose.

Men with pregnant partners should use condoms during intercourse for the duration of the study and until the end of estimated relevant potential exposure to the fetus, predicted to be 6 months after the last dose.

### **Acceptable Methods of Contraception**

Highly effective methods of contraception (less than 1% failure rate) comprise, but are not limited to

- combination oral contraceptives
- implanted contraceptives, or
- intrauterine devices.

Effective methods of contraception comprise but are not limited to diaphragms with spermicide or cervical sponges.

Men and their partners may choose to use a double-barrier method of contraception that must include use of a spermicide.

### **Other Guidance**

Men should refrain from sperm donation for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 6 months after the last dose.

Men who are in exclusively same sex relationships, as their preferred and usual lifestyle, are not required to use contraception.

### 10.3. Appendix 3: Recommended Laboratory Testing for Hypersensitivity Events and Infusion-related Reactions

Recommended laboratory tests should be performed at the time of a systemic hypersensitivity event. The management of the adverse event may warrant laboratory testing beyond that described below and should be performed as clinically indicated.

Laboratory testing during a Systemic Hypersensitivity Event is performed to

- help characterize and classify systemic hypersensitivity reactions
- meet regulatory expectations, and
- improve subsequent clinical management by helping to distinguish between the various mechanistic bases of anaphylaxis.

If anaphylaxis is suspected or generalized urticaria is present, then

1. obtain a sample within 1 to 2 hours of the event.
  - a. samples may be obtained as late as 12 hours after the event as analytes can remain altered for an extended period of time
2. record the time at which the sample was collected, and
3. obtain a follow up sample at the next regularly scheduled visit or after 4 weeks, whichever is later.

#### Laboratory Tests for Hypersensitivity Events

Test	Details
Tryptase	If a tryptase sample is obtained more than 2 hours after the event (i.e., within 2 to 12 hours), or is not obtained because more than 12 hours have lapsed since the event, then obtain urine for <i>N</i> -methylhistamine (NMH) testing. For tryptase serum samples obtained within 2 to 12 hours of the event, urine NMH testing is performed in addition to tryptase testing. Collect the first void urine following the event. Obtain a follow up urine for NMH testing at the next regularly scheduled visit or after 4 weeks, whichever is later.
Anti-drug antibody (ADA)	ADA testing should include drug specific IgE or the basophil activation test (BAT). The BAT requires a serum sample
LY3016859 pharmacokinetic concentration	
Complement	C3a, C5a
Cytokines	IL-6, IL-1 $\beta$ , IL-10 (or any cytokine panel that includes these 3 cytokines)

All tests will be performed by a Lilly-designated central laboratory.

## 11. References

- Juhasz E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. *Eur J Cancer*. 2013;49(6):1205-1215.
- Kersten C, Cameron MG. Cetuximab alleviates neuropathic pain despite tumour progression. *BMJ Case Rep*. 2012;2012.
- Kersten C, Cameron MG, Mjaland S. Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series. *Scand J Pain*. 2013;4(1):3-7.
- Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain. *Br J Anaesth*. 2015;115(5):761-767.
- Martin LJ, Smith SB, Khoutorsky A, Magnussen CA, Samoshkin A, Sorge RE, Cho C, Yosefpour N, Sivaselvachandran S, Tohyama S, Cole T, Khuong TM, Mir E, Gibson DG, Wieskopf JS, Sotocinal SG, Austin JS, Meloto CB, Gitt JH, Gkogkas C, Sonenberg N, Greenspan JD, Fillingim RB, Ohrbach R, Slade GD, Knott C, Dubner R, Nackley AG, Ribeiro-da-Silva A, Neely GG, Maixner W, Zaykin DV, Mogil JS, Diatchenko L. Epiregulin and EGFR interactions are involved in pain processing. *J Clin Invest*. 2017;127(9):3353-3366.

Leo Document ID = 673e7b7f-a892-4ab1-b712-31e1550cddf0

Approver: PPD [REDACTED]

Approval Date & Time: 27-Mar-2020 14:39:21 GMT

Signature meaning: Approved

Approver: PPD [REDACTED]

Approval Date & Time: 27-Mar-2020 20:24:11 GMT

Signature meaning: Approved